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Abstract 
Cognitive stimulation (CS) is a non-pharmacological intervention often involving group 
activities and social interaction used to treat cognitive declines in people with dementia. This 
pre-registered systematic review and meta-analysis evaluated the effectiveness of CS in 
producing benefits on cognition (primary outcome) and quality of life, activities of daily 
living, and psychological symptoms (secondary outcomes) across 44 randomized-controlled 
trials comprising 45 comparisons including 2,444 participants. A medium-sized effect (g = 
0.49) on global cognition was found immediately after the intervention and was supported by 
decisive Bayesian evidence. Clinical relevance is defined as a reduction of 3 to 4 points on the 
ADAS-Cog scale; the average attenuation of cognitive decline observed was 2.41 points (after 
removing one outlier). Therefore, the observed decline was of borderline clinical relevance. 
CS was also found to significantly improve memory, activities of daily living, depressive 
symptoms, and dementia ratings; most of these effects were supported by substantial and 
strong Bayesian evidence. No significant effects were found for global cognition at 1 to 10 
months follow-up assessment, for language, quality of life, anxiety, and behavior symptoms. 
However, evidence for the absence of these effects was ambiguous. A review of study bias 
highlighted that most studies lacked active, double-blinded controls, potentially leading to an 
overestimation of the effect, and making it difficult to conclusively attribute the observed 
improvements to the CS intervention. Hence, although effects are promising, the 
methodological issues highlight there is still a need for better controlled studies that provide 
more compelling evidence.  
Keywords: cognitive stimulation, dementia, cognitive decline 
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Public Significance Statement 
Cognitive stimulation is a psychosocial, nonpharmacological treatment for people with 
dementia. This meta-analysis of 44 randomized-controlled trials shows that cognitive 
stimulation does benefit global cognition, memory, activities of daily living, depressive 
symptoms, and dementia ratings. However, these benefits are of only borderline clinical 
relevance. Furthermore, our review identifies several methodological challenges that this 
research area faces, calling for investment into better controlled studies to provide robust and 
compelling evidence for the effectiveness of cognitive stimulation as a treatment for people 
with dementia.  
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Effectiveness of Cognitive Stimulation for Dementia: A Systematic Review and Meta-
Analysis 
Dementia is an umbrella term for a range of conditions caused by neurodegeneration, 
including Alzheimer’s disease, vascular dementia, frontotemporal dementia, and Lewy body 
dementia. It is characterized by a progressive decline in cognitive ability of sufficient severity 
to interfere with social and/or occupational functioning. It may also include other symptoms 
such as language problems, deterioration in the ability to perform activities of daily living, 
and behavior changes (Innes & Manthorpe, 2013; Kitwood, 1997). With 50 million people 
worldwide currently living with dementia – a number that is bound to triple to 152 million by 
2050 – and an estimated associated economic cost of USD 1 trillion thought to double by 
2030 (Alzheimer’s Disease International [ADI], 2018), it has become a global priority to seek 
ways to ameliorate the detrimental health and financial impacts of dementia (World Health 
Organization [WHO], 2018). Yet, drug development efforts have been characterized by a high 
failure rate (99.6% for clinical trials for drugs targeting Alzheimer’s disease, Cummings et al., 
2014), and existing pharmacological treatments aimed to alleviate cognitive, behavioral, and 
psychological symptoms of dementia have raised concerns about adverse side-effects and 
mortality risks (Ballard et al., 2009; Maust et al., 2015). Consequently, psychosocial, non-
pharmacological interventions are increasingly considered a core component of dementia care 
(Kenigsberg et al., 2016), as they can provide a safe and cost-effective means to support 
people with dementia (Livingston et al., 2014; McDermott et al., 2019; Nyman & 
Szymczynska, 2016).  
Cognitive stimulation (CS) is a particularly promising psychosocial intervention 
recommended for people with mild-to-moderate dementia (National Institute for Health and 
Care Excellence [NICE], 2018). CS aims to improve global cognition and maintain function 
by stimulating multiple cognitive functions simultaneously, typically with group activities 
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emphasizing social interaction. This approach is different from cognitive training, which 
targets isolated cognitive functions (e.g., memory) with individual, repetitive practice of 
standardized cognitive tasks. CS is also distinguished from cognitive rehabilitation, a person-
centered approach that aims at improving everyday life through developing strategies for 
performing desired functions or tasks (Clare & Woods, 2004). Whereas there is limited 
evidence for the effectiveness of cognitive training for people with mild to moderate dementia 
(e.g., Bahar-Fuchs et al., 2013; Bahar-Fuchs et al., 2020; Hill et al., 2017), and only few 
studies assessing benefits of cognitive rehabilitation (but see Clare et al., 2010), CS has 
received consistent meta-analytic support for improved cognitive performance (Aguirre et al., 
2013; Huntley et al., 2015; Kim et al., 2017; Kurz et al., 2011). Moving beyond previous 
meta-analyses, in the present work, we compared the effects of different CS approaches 
considering moderators on a wide range of outcomes.  
Cognitive Stimulation Approaches 
CS encompasses a variety of approaches including reality orientation, validation, 
and/or reminiscence. Reality orientation involves consistent repetition of facts of life, for 
example a person’s name, where they live, and the current date. Reality orientation is 
administered in intensive formal classroom periods of 30-60 minutes. Instead of classes or as 
a supplement to classes, reality cues are provided throughout everyday life, for example on 
blackboards that list the name of the hospital, its location, and the current date. Although 
reality orientation can have measurable benefits on cognitive and independent functioning 
(Holden & Woods, 1995; Spector et al., 2000), it has also attracted criticism. Powell-Proctor 
and Miller (1982) pointed out that reality orientation as a technique is defined only vaguely 
and, thus, its interpretation and translation into practice varies greatly. Moreover, the sole 
focus of reality orientation on communicating information and instructions can be 
experienced as distressing. For example, Dietch et al. (1989) reported the case of a woman 
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who became upset when staff emphasized that her son was not seven years old (as she 
remembered) but instead much older.  
Validation and reminiscence approaches address the potentially distressing aspects of 
reality orientation. Validation focuses on empathic listening and the person’s subjective 
experience as opposed to objective facts. Reminiscence involves discussing past events and 
reflecting on a person’s life using prompts such as photographs, music and videos.  
Incorporating elements of reality orientation, validation, and reminiscence, Spector et 
al. (2001) developed CS therapy (CST), a structured and manualized psychosocial 
intervention (Spector et al., 2006) targeting cognitive and social abilities. Typically, CST is 
delivered over a period of seven weeks, with two sessions per week each lasting around 45 
minutes. The 14 sessions are underpinned by 18 guiding principles (Spector et al., 2006), 
including encouraging mental stimulation; using orientation, both sensitively and implicitly; 
eliciting opinions rather than facts; using reminiscence as an aid to the here-and-now; 
providing triggers to aid recall; and building/strengthening relationships. To aid reality 
orientation, a board is used in every session that shows personal and orientation information. 
Each session follows a different theme (e.g., physical games, sound, or using money) with a 
range of activities that can be tailored to the groups’ interests.  
Prior Reviews 
Four previous reviews examined CS benefits for people with dementia. Kurz et al. 
(2011) reviewed 18 randomized-controlled trials (RCT) of CS interventions that assessed 
cognitive outcomes in people with a diagnosis of mild cognitive impairment (MCI) or 
dementia. Compared to control conditions, CS was found to significantly improve indicators 
of global cognition, with standardized mean differences (SMD) ranging from 0.21, 95% 
confidence interval (CI) = [0.03, 0.39] for the Mini-Mental State Examination (MMSE; 
Folstein et al., 1975) to SMD = -0.30, 95% CI [-0.48, -0.13] on the Alzheimer’s Disease 
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Assessment Scale Cognitive subscale (ADAS-Cog; Rosen et al., 1984). No significant 
improvements of activities of daily living were found across the 9 studies reporting 
corresponding measures. However, Kurz et al. (2011) did not report the effects of CS 
specifically for people with dementia (k = 13). Moreover, too few studies were available at 
the time of their review to test other secondary outcomes such as quality of life, mood 
(indicators of depression and anxiety), and behavioral and psychological symptoms. 
Similarly, too little data were available to test for the effects of potential moderators on the 
benefits of CS.  
Aguirre et al. (2013; see also Woods et al., 2012) reviewed 15 RCTs with a duration of 
at least 4 weeks and where at least one cognitive outcome was assessed. Aguirre et al. focused 
exclusively on CS interventions and samples of people with a diagnosis of dementia. Notably, 
their meta-analysis did not include seven of the studies included in Kurz et al. (2011) that, in 
our reading, would have been eligible. Still, like Kurz et al. (2011), Aguirre et al. (2013) 
found a significant positive effect of CS on global cognition; SMD = 0.41, 95% CI = [0.25, 
0.57]. Moreover, tentative evidence based on three studies suggested that the CS benefits 
lasted up to 3 months after the intervention, whereas no long-term benefits were found in one 
study that assessed CS effects after 10 months. The authors also examined a range of 
secondary outcomes including quality of life, activities of daily living, mood, and behavior. 
The only significant effect was found for quality of life ratings (SMD = 0.38, 95% CI = [0.11, 
0.65]); however, estimates for these secondary outcomes were based on only small sets of 
studies (ks = 4 to 8).   
Huntley et al. (2015) analyzed data from 22 RCTs investigating the benefits of CS 
interventions for people with dementia and confirmed the findings of previous meta-analyses, 
with average effects ranging from g = -0.26, 95% CI [-0.44, -0.08] (ADAS-Cog) to g = 0.51, 
95% CI [0.35, 0.66] (MMSE) for comparisons to passive control groups. Participants in 
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passive (or waiting list) control groups typically receive treatment as usual, thereby 
controlling for effects of repeated testing arising from pre-/post-test designs. In contrast, 
participants in active control groups undergo an alternative intervention designed to have no 
effect on the targeted mechanisms while appearing to be a plausible treatment. In addition to 
retest effects, active control groups control for generic, non-specific intervention effects such 
as attention from research teams, and expectancy effects (e.g., Oken et al., 2008; see also von 
Bastian & Oberauer, 2014). At the time of their review, Huntley et al. (2015) identified only 
three studies that compared effects of CS to active control interventions. Although still 
significant, the average effect on the MMSE was considerably smaller, g = 0.35, 95% CI 
[0.06, 0.64]; at the time, none of the studies with active controls evaluated effects on the 
ADAS-Cog. These findings demonstrate the importance of accounting for risks of biases from 
suboptimal controls. Huntley et al. further evaluated a number of moderators, including 
context (inpatient or outpatient), intervention duration, format, and intensity, and baseline 
MMSE. None of the moderators was significant; importantly though, Huntley et al. tested 
these moderators only for effect sizes pooled across CS and other cognition-focused 
interventions (cognitive training and cognitive rehabilitation). Therefore, it remains unclear 
whether any of the moderators may specifically affect effects of CS.  
Most recently, Kim et al.’s (2017) review of 12 RCTs that assessed cognitive 
outcomes confirmed previous findings with SMD = 0.44, 95% CI [0.27, 0.60]. The authors 
also examined CS benefits for a range of secondary outcomes. Like Aguirre et al. (2013), they 
found a significant effect only for quality of life (SMD = 2.05, 95% CI [0.72, 3.38]) but not 
for activities of daily living, mood, or behavior and psychological symptoms. However, as 
Kim et al. (2017) included substantially fewer studies than previous reviews (for unclear 
reasons), estimates for these secondary outcomes were again based on only a few studies (ks 
between 1 and 6). Furthermore, Kim et al. (2017) noted a lack of double-blinded studies, 
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which could add to confounds from expectancy effects, and a large heterogeneity in study 
settings and components of CS interventions. 
Present Study 
The cumulative evidence from previous reviews suggests positive effects of CS on 
indicators of global cognition, with tentative evidence supporting benefits also on quality of 
life (Aguirre et al., 2013; Kim et al., 2017). However, these previous estimates were based on 
relatively few studies, which is particularly problematic considering the risk of bias identified 
in previous reports. Moreover, the limited number of studies permitted neither distinguishing 
between different CS approaches nor examining intervention- and sample-specific factors that 
could impact the effectiveness specifically of CS and specifically for people with dementia.  
The present pre-registered systematic review and meta-analysis updates previous 
reports by including 44 studies. Furthermore, moving beyond previous reviews, the present 
work investigates the benefits of CS for people with dementia for a range of outcomes and 
considering potential moderators. Like Aguirre et al. (2013) and Kim et al. (2017), we 
considered primary outcomes (global cognition, memory, and language) as well as secondary 
outcomes (quality of life, activities of daily living, mood, and behavior and psychological 
symptoms). Critically, the larger number of studies also allowed for examining a range of 
moderators of CS benefits. Like Huntley et al. (2015), we considered both intervention- and 
sample-specific moderators including treatment dosage (duration, frequency, and number of 
sessions of the intervention), intervention context, and baseline MMSE. Different to Huntley 
et al., though, our analyses focus specifically on CS interventions. In addition, we tested the 
impact of the type of CS intervention (CST or reality orientation), number of CS components, 
and demographic factors (age and gender). Given the discussion of the possible impact of the 
biases identified by Huntley et al. (2015) and Kim et al. (2017), analyses were complemented 
by a careful risk of bias assessment, and Bayes factors (BF) for each estimate as a measure of 
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the strength of evidence. Finally, different from the previous meta-analyses – except Huntley 
et al. (2015) –, we adopted a random-effects modeling approach to account for the large 
variability in samples and methods of the empirical studies (Field et al., 2010).  
Method 
The present systematic review and meta-analysis builds directly on the prior review by 
Aguirre et al. (2013) and was designed to follow PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines (Moher et al., 2009). The study protocol 
detailing the review question, search strategy, inclusion criteria, and analytical methods was 
preregistered with PROSPERO on May 23, 2018 (CRD: 42018096652). 
Search Method 
Figure 1 illustrates the search and selection process. As the article by Aguirre et al. 
(2013) was the most comprehensive meta-analysis focusing specifically on CS that we were 
aware of at the time of our search, we updated their set of 15 studies reported by using 
identical keywords (“cognitive stimulation”, “reality orientation”, “memory therapy”, 
“memory groups”, “memory support”, “memory stimulation”, “global stimulation”, and 
“cognitive stimulation”) to search healthcare databases (MEDLINE, PsycINFO, CINAHL, 
and LILACS), trial registers (Cochrane Central Register of Controlled Trials [CENTRAL], 
UK Clinical Trials Gateway, ISRCTN, WHO Portal, and UMIN Japan Trial Register), and 
gray literature sources (Web of Science, ProQuest, Australian Digital Theses, OpenGrey). For 
published work (but not for unpublished work and theses), we restricted the search to reports 
published after 2011 (the date when Aguirre et al., 2013, concluded their search). We carried 
out the search on June 19, 2018, which resulted in 2,923 references. In addition, we examined 
the bibliographies and citations of relevant articles, which yielded 8 additional reports. We 
also considered the overall 21 reports that were not included in Aguirre et al.’s (2013) article 
but in the previous reviews by Kurz et al. (2011), Huntley et al. (2015), and Kim et al. (2017). 
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We also contacted the first authors of all included reports to inquire about unpublished work 
or published work that was not yet included, which resulted in one additional report. Finally, 
we ran a search update on Google Scholar on June 7, 2020, which resulted in an additional 6 
reports. After duplicates removal and initial screening, we assessed 124 full texts for inclusion 
eligibility.  
Inclusion and Exclusion Criteria 
We included journal articles, theses, and book chapters written in English and 
reporting empirical data of at least one measure of cognitive functioning from an RCT. 
Participants had to be diagnosed with any type of dementia and have received CS for at least 
four weeks consistent with the definition proposed by Clare and Woods (2004). This included 
reality orientation, CST, reminiscence therapy, or other CS interventions fulfilling Clare and 
Wood’s criteria, that is, they consisted of a wide range of activities that are completed in a 
group format with social interaction and aim to improve overall cognition rather than a single 
cognitive function. Of the 124 full texts assessed, 49 studies met the criteria. However, the 
data reported in two of these studies (Graessel et al., 2011; Luttenberger, Donath, et al., 2012) 
overlapped with the data reported in an article already included (Luttenberger, Hofner, & 
Graessel, 2012) and, thus, were excluded. Three other studies did not report sufficient data to 
compute effect sizes (D’Amico et al., 2015; Quayhagen et al., 2000; Yamanaka et al., 2013). 
For two further studies that also did not report sufficient data to compute effect sizes (Baldelli 
et al., 1993; Chapman et al., 2004) and one study (Ferrario et al., 1991) that could not be 
accessed, we used the data reported in Aguirre et al. (2013) in the present analysis. The final 
set of 44 included studies yielded k = 45 comparisons.  
Data Extraction 
Two independent coders (RC and BH) extracted the relevant data from each study 
based on a coding protocol (see https://osf.io/8mwnt/) that detailed which information to 
COGNITIVE STIMULATION REVIEW 12 
extract and how (e.g., an explanation of what is regarded an independent comparison; 
decision-rules which numbers to extract in case the in-text reporting deviated from 
information listed in tables). The two coders independently entered their data in a mySQL 
database through a web interface. The web interface – a multipage form – was implemented 
with the open-source framework Grocery CRUD (version 1.5.0, Skoumbourdis, 2014). Data 
were stored in a mySQL database to facilitate handling of nested data (e.g., multiple 
comparisons from the study, multiple outcomes for the same comparisons), and automatized 
comparison of data entered by different coders. Both coders were involved in piloting and 
revising the coding protocol based on a set of five studies. Any discrepancies between coders 
were resolved by discussion and involving a third reviewer (CvB). Interrater reliabilities for 
categorical moderators were κ = .90 (type of intervention) and κ = .71 (sample from urban vs. 
rural area). 
The information extracted from studies included (a) bibliographic information (e.g., 
publication author, title, year, and publication status), (b) intervention descriptors (e.g., CS 
content and components, duration and number of sessions, intervention setting)1, (c) sample 
descriptors (e.g., age, gender, demographic background, diagnosis, medication, baseline 
MMSE score/clinical severity), and (d) outcomes (measure, sample size, means and standard 
deviations, direction of the effect). Where means and standard deviations were not available, 
effect sizes were estimated based on statistical values reported (e.g., F-statistic).  
Outcomes 
Primary Outcomes 
To assess meta-analytic effects of CS on target areas of cognitive function, we 
extracted effects on global cognition measures (e.g., ADAS-Cog, MMSE). In addition, we 
 
1 We originally planned to code also the intervention schedule, living situation, and average time since 
the diagnosis. However, during the literature review we found that too few studies reported this information and, 
therefore, decided not to code these variables. 
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coded effects of CS on memory (e.g., word recall) and language (e.g., verbal fluency). 
Maintenance effects2 were coded as follow-up data of CS effects on global cognition one 
month or longer after posttest.  
Secondary Outcomes  
In addition to cognitive benefits, we preregistered to evaluate effects of CS on quality 
of life (Logsdon et al., 1999), activities of daily living (Lawton & Brody, 1969), depression 
(D’Ath et al., 1994) and anxiety (Shankar et al., 1999), and behavior (Pattie & Gilleard, 1975) 
and psychological (Hughes et al., 1982) symptoms.  
Analysis 
For all statistical analyses, we used R. Scripts and data are available on the Open 
Science Framework (https://osf.io/8mwnt/).  
Calculation of Effect Sizes 
We computed standardized mean between-groups differences (Cohen’s d) of change 
scores. We used pooled SDs at pretest where available as they provide least biased effect size 
estimates (Morris, 2008). In three studies, the pretest SDs reported and used for computing the 
effect size were for a different subsample (Alves et al., 2014; Chapman et al., 2004; Onder et 
al., 2005). In two studies, pretest SDs were not available and posttest SDs were used instead 
(Baglio et al., 2015; Kolanowski et al., 2016). In two studies where neither pretest nor posttest 
SDs were available (Breuil et al., 1994; Ferrario et al., 1991), change score SDs were used. As 
change score SDs are typically smaller than pretest and posttest SDs, effect sizes from these 
two studies are likely overestimated. However, because sensitivity analyses excluding these 
two studies yielded identical conclusions, we decided to report the findings from the analyses 
including these two studies. Effect size estimates were corrected for small sample bias using 
Hedges’ g (Borenstein et al., 2009).  
 
2 Note that maintenance effects were preregistered as a potential moderator in the preregistration but 
treated as outcome in the report.  
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Pooling of Dependent Effect Sizes 
Several studies provided multiple measures of an outcome; in particular, effects of CS 
were often reported for both the ADAS-cog and the MMSE. To avoid biased estimates arising 
from including multiple measures from the same sample (Borenstein et al., 2009; Cooper et 
al., 2009), we originally planned to compute composite effect size estimates. However, we 
later became aware of evidence that the ADAS-Cog measurement is a more precise measure 
for people with dementia that more accurately discriminates between levels of cognitive 
dysfunction (Balsis et al., 2015). Moreover, the ADAS-Cog is primarily used in 
pharmacological interventions (Schneider et al., 2014) and, thus, allows for better 
comparisons to CS intervention studies. Therefore, we decided to include only the ADAS-
Cog scores but discard the MMSE scores where both were reported. For all other outcomes, 
we classified measures based on the authors’ reporting. For the few studies that used multiple 
memory measures, we selected episodic memory measures over short-term memory 
measures, and short-term memory measures over working memory measures. For the one 
study reporting two quality-of-life measures (Gibbor et al., 2020), we selected the self-report 
measure and discarded the carer-reported measure.  
Meta-Analytic Procedures 
Mean effect sizes were estimated with random-effects models assuming sampling 
error within and across studies, thereby allowing for generalization of our findings (Field et 
al., 2010). Homogeneity of effect sizes was tested conducting Q tests and examining I2 
statistic and the variability parameter τ. Given the low number of studies reporting moderator 
data, we ran separate meta-regression Q tests for each moderator with at least 10 cases for 
each category (Deeks et al., 2011). In addition, we estimated the average effect sizes and 
associated 95% confidence intervals (CIs) for each level of tested moderator. Meta-analysis 
was conducted with the metafor package (Version 2.0.0., Viechtbauer, 2010), using a 
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restricted maximum-likelihood estimator with Knapp and Hartung (2003) adjustment to the 
standard errors of the estimated coefficients (Viechtbauer et al., 2015).  
Although the present meta-analysis comprised more comparisons than its 
predecessors, the number of cases was still relatively low, in particular for conducting meta-
regression, which may lead to low statistical power (Schmidt, 2017). However, estimating 
power for meta-analysis is challenging because it requires a series of assumptions about 
unknown parameters (Valentine et al., 2010). Similarly, arbitrary rules of thumb (such as the 
preregistered minimum number of 10 cases used in the present study) are unsatisfying. In 
addition, the reliabilities of the measures typically used to assess the outcomes evaluated in 
this meta-analysis can be relatively low. For example, with increasing time interval between 
tests, reliabilities of change scores derived from the ADAS-Cog tend to be low (e.g., ranging 
between .53 to .64 after 1 year in Grochowalski et al., 2016). Ideally, the measurement error 
arising from low reliability coefficients should be corrected (Schmidt & Hunter, 2015). 
However, reliability estimates are rarely reported in the literature included in this meta-
analysis. Moreover, the outcomes assessed in this meta-analysis include a variety of 
instruments (e.g., ADAS-Cog, MMSE, and the Cognitive Assessment Scale of the Clifton 
Assessment Procedures for the Elderly [CAPE], Pattie & Gilleard, 1975), each of which is 
associated with different reliabilities. Therefore, it would have been difficult to justify picking 
a particular (set of) reliability estimates for correcting the reported effect sizes. Instead, we 
addressed the uncertainty associated with potentially low statistical power and measurement 
reliability by computing BFs for average effect-size estimates as well as for the inclusion of 
moderators. BFs cannot correct for low statistical power or measurement error, but they 
provide a measure of the strength for the evidence in the given data, thereby allowing for 
gauging the extent to which effect sizes need to be interpreted more carefully.  
Bayes Factors  
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BFs were estimated for each study, the average effect-size estimates for each outcome 
and level of each tested moderator, and for the inclusion of moderator variables in the meta-
regressions. A BF is the ratio of the probability of the data under one hypothesis relative to 
the probability of the data under the other hypothesis, with values ranging on a continuous 
scale from 0 to ∞. As the BF is a ratio, a value of 1 reflects perfect ambiguity. The greater the 
BF, the stronger the evidence in favor of the hypothesis in the numerator (typically the 
alternative hypothesis, H1), with values below 1 reflecting evidence in favor of the hypothesis 
in the denominator (typically the null hypothesis, H0). For example, BF = 10 indicates that the 
data are 10 times more likely under H1 than under H0; in contrast, BF = 1/10 reflects that the 
data are 10 times more likely under H0 than under H1. Conventionally, BFs between 1/3 and 3 
are considered ambiguous evidence. Table 1 lists verbal labels of BF ranges to facilitate 
understanding (Wetzels & Wagenmakers, 2012).  
Study-level BFs were computed using the BayesFactor package (Version 0.9.12.4.2, 
Morey & Rouder, 2015), with BFs based on the t-statistics (Rouder et al., 2009) derived from 
the computed Hedges’ g using the BSDA package (Version 1.2.0, Arnholt & Evans, 2017). 
Meta-analytic BFs were computed using the metaBMA package (Version 0.3.9, Heck, 
Gronau, & Wagenmakers, 2017). We pre-registered our priors for both effect-size estimates 
and the homogeneity parameter τ. For effect-size estimates, we chose a Cauchy distribution 
with a scaling factor r = 0.41 reflecting the average effect size reported by Aguirre et al. 
(2013). We truncated the distribution at 0 to reflect the one-tailed hypothesis that CS should 
improve (and not worsen) the outcomes. The Cauchy distribution is a t distribution with a 
single degree of freedom. It is similar to a normal distribution, except that it has fatter tails, 
thereby allowing more mass on larger effects (Rouder et al., 2009). The Cauchy distribution is 
widely used to compute BFs since it has been introduced for specifying the prior by Jeffreys 
(1961), which facilitates the interpretation of the BFs reported in the present article to those 
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reported in other work. Sensitivity analyses were conducted for d = 0.20 and d = 0.80 to 
reflect small and large effect sizes, respectively. For the homogeneity parameter τ, we used an 
inversed Gamma distribution (α = 1.23, β = 0.16 and boundaries ranging from 0.01 to ∞). 
This prior distribution is based on the heterogeneity observed in mean-difference effect sizes 
reported in Psychological Bulletin between 1990 and 2013 (Gronau et al., 2017; van Erp et 
al., 2017). Using such an informed prior formalizes the existing knowledge about the relative 
probability of values for parameters, which improves the estimates of the effect sizes and their 
heterogeneity and, thus, yields also more informative BFs (for more detailed discussions of 
the benefits of using informed priors, see Lee & Vanpaemel, 2018; Steel et al., 2014). Using 
the default prior for the homogeneity parameter τ (an inversed Gamma distribution with α = 
1.00, β = 0.15) led to same conclusions.  
Risk of Bias  
For each study, coders independently rated risk of bias from six sources: random 
sequence generation for random allocation of participants to conditions, allocation 
concealment, blinding of participants, blinding of assessors, participant attrition, and 
completeness of reporting using the Cochrane Risk of Bias Tool (Higgins et al., 2011). One 
point was awarded for low risk of bias, -1 point for high risk of bias, and 0 points for unclear 
risk of bias for each of the six sources. As for categorical moderators, discrepancies between 
coders were resolved by discussion and involving a third reviewer (CvB). Interrater reliability 
was κ = .63.  
As small-sample studies can yield biased results, we visually examined funnel plots 
depicting effect sizes against their precision and tested for asymmetry using Egger’s 
regression (Egger et al., 1997) and Begg and Mazumdar’s (1994) rank correlation. We further 
pre-registered to conduct a p-curve analysis (Simonsohn et al., 2014); however, 29 out of the 
44 studies had to be excluded from p-curve analysis for various reasons (e.g., non-significant 
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results: k = 4, not reporting the statistics to compute required p-values: k = 18). We therefore 
deemed the analysis not reflective of the full sample of studies and refrained from reporting it 
here. For the sake of completeness, the p-curve disclosure table and results can be found on 
OSF (https://osf.io/8mwnt/). Finally, we were unable to conduct the pre-registered 
comparison between published and unpublished studies as a measure for publication bias as 
we did not identify unpublished data in the search.  
Results 
Table 2 lists descriptive information of the 44 included studies yielding k = 45 
comparisons that reported data from 2444 participants (experimental n = 1,300, age M = 
80.47 years, SD = 6.39; control n = 1,144, age M = 80.15 years, SD = 6.68). Most participants 
were diagnosed with Alzheimer’s disease (k = 22 comparisons). In two studies, participants 
were diagnosed with vascular dementia, and in six other studies samples consisted of 
participants diagnosed with diverse types of dementia. Studies varied in the interventions 
administered. Twelve administered CST as described by Spector et al. (2001), with one of 
them also involving exercise. Eleven studies used some other form of CS according to Clare 
and Woods’ (2004) definition, with four of them also involving exercise and one of them also 
involving reality orientation. Of the 15 studies primarily administering some form of reality 
orientation, two studies also used exercise, and five studies combined it with reminiscence 
activities. Six further studies used reminiscence (k = 7, as one study included two 
comparisons), with one of them combining reminiscence with exercise.  
Eight studies compared CS to an active control group. Active control activities varied 
in the degree to which they involved group interactions and/or structured activities. In two 
studies (Capotosto et al., 2017; Piras et al., 2017), sessions dedicated to reading newspaper 
articles or stories from books with subsequent group discussions were alternated with sessions 
focusing on creative activities such as coloring, painting, decorating, or cooking. Woods et al. 
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(1979) engaged active control participants in unstructured group discussions and occasional 
board games, and Buschert et al. (2011) administered monthly group meetings in which 
participants completed paper-pencil exercises for self-study. In the study of Wallis et al. 
(1983), active control participants could freely choose between a range of not further 
described group and individual activities. Niu et al. (2010) engaged participants in the active 
control group in unstructured, individual conversational interactions. Baldelli et al. (2002) 
administered regular physical rehabilitation, but it is unclear whether it was administered 
individually or in a group setting. In the study of Quayhagen et al. (1995) the degrees of 
group interaction and structure are unclear, with the control intervention involving explicitly 
passive, observational activities (e.g., watching TV). 
Most studies were conducted in Europe (k = 29), most of them in Italy (k = 10), 
followed by the UK (k = 8). Seven studies were conducted in Asia (k = 8, as one study 
included two comparisons), three in North America, two in South America, and one in Africa; 
for two studies the information where they conducted the intervention was not available. 
Table 3 lists the effect sizes and strength of evidence for the primary (global cognition, 
memory, and language) and secondary outcomes (quality of life, activities of daily living, 
depression, anxiety, dementia, and behavior). Table 4 lists the results for the moderators 
tested for each outcome.  
Primary Outcomes 
Global Cognition 
Effects of CS on global cognition (k = 42) were predominantly assessed with the 
ADAS-Cog (k = 17) or MMSE (k = 19).  
Average Effect at Posttest. Figure 2 illustrates the distribution of effect sizes from 
single studies and the strength of their associated evidence. Like Aguirre et al. (2013), we 
found a medium-sized effect of CS on global cognition, g = 0. 49, 95% CI [0.35, 0.63], t = 
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6.95, p < .001. Evidence for this effect was decisive, BFH1 = 3,345,365.05. Effect size 
estimates from single studies ranged from g = -0.19 (Coen et al., 2011) to g = 1.71 (Baglio et 
al., 2015). The evidence of 69% of studies was ambiguous only (i.e., BFs between 1/3 and 3). 
Of the studies that did contribute more substantial evidence (i.e., BFs greater than 3 or smaller 
than 1/3), 92% favored benefits of CS on global cognition. The heterogeneity in effect sizes 
was significant, Q(41) = 92.56, p < .001, with an estimated true between-studies variance τ2 = 
0.10 (SE = 0.05). Evidence for the heterogeneity in effect sizes was decisive, τ2 BFH1 = 
26,306.06. The proportion of variability from true heterogeneity relative to that from 
sampling error was moderate, I2 = 54.68, 95% CI [28.52, 72.56].  
None of the variables significantly moderated the effects of CS on global cognition (ps 
≥ .230), with the residual heterogeneity remaining significant (all ps < .01). The evidence 
consistently supported the absence of moderator effects, with most BFH1 < 1/3. The only 
exception was observed for the effect of type of intervention, BFH1 = 1/2.33. The average 
effect of interventions involving some form of reality orientation was numerically larger than 
that for interventions involving CST, with stronger evidence for the effectiveness of reality 
orientation (BFH1 = 129.07) than for CST (BFH1 = 13.39). Because of the practical relevance 
of the intervention-specific categorical moderators, we illustrate the effect sizes for each level 
of moderator in Figure 3. 
Only eight studies compared the effects of CS to an active control group. Although we 
preregistered to only test moderators with at least 10 cases per level, we decided to explore 
the effect of this critical methodological feature on the overall effect size given its clinical 
importance. For example, a substantially smaller average effect size for actively controlled 
studies than passively controlled studies would suggest that CS benefits were primarily due to 
expectancy and non-generic intervention effects (e.g., effects from committing to and 
participating in a regular activity). However, effect sizes did not differ significantly between 
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studies with active and passive controls, F(1, 40) = 0.27, p = .606, with strong evidence 
supporting the absence of an effect, BFH1 = 1/4.28 (small-effect prior: BFH1 = 1/2.18, large-
effect prior: BFH1 =  1/6.47). Numerically, the effect was smaller for actively controlled 
studies though, g = 0.41, 95% CI [0.18, 0.65], t = 4.14, p = .004, than for passively controlled 
studies, g = 0.51, 95% CI [0.34, 0.68], t = 6.10, p < .001, and the strength of evidence was 
weaker in the set of actively controlled studies, BFH1 = 24.40 (small-effect prior: BFH1 = 
22.30, large-effect prior: BFH1 = 19.04), than in the set of passively controlled studies, BFH1 = 
105,213.31 (small-effect prior: BFH1 = 76,025.55, large-effect prior: BFH1 =  95,486.87). 
However, the relatively weaker evidence may be due to the smaller number of studies with 
active controls.  
Average Effect at Follow-Up. Aguirre et al. (2013) reported some initial evidence for 
long-term effects of CS on global cognition based on four studies. Meanwhile, nine of the 
studies included in the present analysis tested long-term effects at follow-up 1 to 10 months 
after the intervention. Different from Aguirre et al.’s findings, the average effect was small 
and non-significant, g = 0.22, 95% CI [-0.09, 0.54], t = 1.64, p = .140. However, the evidence 
was ambiguous, BFH1 = 1.67, likely due to the still small number of studies testing for follow-
up effects. Heterogeneity in effect sizes was not significant, Q(8) = 11.18, p = 0.192, τ2 = 0.03 
(0.06), τ2 BFH1 = 1/1.17, I2 = 19.10, 95% CI [0.00, 84.37]. No moderators were tested given 
the small number of follow-up effect sizes and the non-significant heterogeneity in effect 
sizes.  
Memory 
The average effect of CS on memory (k = 15) was medium-sized, g = 0.34, 95% CI 
[0.06, 0.62], significant, t = 2.61, p = .021, and supported by substantial evidence BFH1 = 
9.74. The heterogeneity in effect sizes was significant, Q(14) = 30.16, p = .007, τ2= 0.12 (SE 
= 0.09), τ2 BFH1 = 9.09, I2 = 53.59, 95% CI [9.27, 83.28]. None of the tested moderators was 
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significant but, notably, the evidence was mostly inconclusive, except in case of the total 
number of sessions, BFH1 = 1/3.20.  
Language 
The average effect of CS on language (k = 14) was small and non-significant, g = 0.10, 
95% CI [-0.47, 0.67], t = 0.38, p = .710. The strength of evidence for the absence of this effect 
was ambiguous, BFH1 = 1/1.89. The heterogeneity in effect sizes was significant, Q(13) = 
86.64, p < .001, τ2 = 0.83 (SE = 0.38), τ2 BFH1 = 2,328,499,419.34, I2 = 88.87, 95% CI [77.94, 
95.94]. None of the tested moderators was significant; however, the evidence was ambiguous 
in all cases.  
Secondary Outcomes 
Quality of Life 
The average effect of CS on quality of life (k = 11) was small and non-significant, g = 
0.16, 95% CI [-0.16, 0.48], t = 1.10, p = .295. Evidence supported the absence of an effect but 
was ambiguous, BFH1 = 1/1.07. Heterogeneity in effect sizes was significant, Q(10) = 18.94, p 
= .041, τ2 = 0.02 (SE = 0.05), τ2 BFH1 = 1.31, I2 = 25.64, 95% CI [0.00, 92.42]. None of the 
tested moderators was significant, with the evidence largely supporting the absence of effects. 
Activities of Daily Living  
The average effect of CS on activities of daily living (k = 14) was small yet 
significant, g = 0.17, 95% CI [0.02, 0.32], t = 2.48, p = .028, but the evidence was ambiguous, 
BFH1 = 2.04. The distribution of effect sizes is illustrated in Figure 4. Effect size estimates 
from single studies ranged from g = -1.07 (Alves, Alves-Costa, Magalhães, Gonçalves, & 
Sampaio, 2014) to g = 0.57 (D’Onofrio et al., 2015). These two studies were also the only 
ones contributing substantial evidence, albeit favoring opposite hypotheses. Evidence from 
the other studies was ambiguous. Heterogeneity in effect sizes was non-significant, Q(13) = 
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12.98, p = .456, τ2 = 0.02 (SE = 0.03), τ2 BFH1 = 1/1.04, I2 = 20.38, 95% CI [0.00, 55.29]. 
Thus, no moderators were tested. 
Depression 
The average effect of CS on depression measures (k = 19) was medium-sized and 
significant, g = 0.46, 95% CI [0.15, 0.78], t = 3.07, p = .007. The evidence supporting this 
effect was strong, BFH1 = 27.26. The distribution of effect sizes is illustrated in Figure 5. 
Effect sizes ranged from g = -0.86 (Requena, Maestú, Campo, Fernández, & Ortiz, 2006) to g 
= 1.97 (Menna, Santaniello, Gerardi, Di Maggio, & Milan, 2016). Evidence from 58% of 
studies was ambiguous. Of the studies that contributed more substantial evidence, 75% 
favored benefits of CS on depression scores. The heterogeneity in effect sizes was significant, 
Q(18) = 68.88, p < .001, τ2 = 0.28 (SE = 0.14), τ2 BFH1 = 118,219.64, I2 = 74.73, 95% CI 
[53.71, 89.65].  
Numerically, the average effect size tended to be greater for interventions that were 
shorter, involved less sessions per week, and entailed a lower number of total sessions, with 
the latter effect being significant, F(1, 17) = 4.90, p = .041. However, evidence for the effects 
of dosage was ambiguous, with BFH1 ranging between 1/1.14 and 2.35. Figure 6 visualizes the 
counterintuitive relationship between dosage and average effect sizes. Visual inspection 
suggested that the negative relationship might be driven by a single study that administered 
five sessions per week over the course of 104 weeks (Requena et al., 2006). Indeed, after 
excluding the study from analysis3, the association between duration and the average effect 
size became positive and significant, F(1, 16) = 5.90, p = .027, BFH1 = 3.41. The associations 
between frequency and total number of sessions and average effect size were also positive, 
albeit non-significant (ps ≥ .563), with the evidence supporting the absence of moderator 
effects (BFH1 = 1/2.69 and 1/3.41, respectively). Evidence was ambiguous regarding the 
 
3We reran the moderator analyses for testing the effects of intervention duration, intensity, and dosage 
for all outcomes when excluding the study by Requena et al. (2006). Results yielded identical conclusions. 
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remaining tested moderators age, gender, and baseline MMSE, with BFH1 ranging between 
1/2.43 and 1.05. The evidence may be ambiguous due to the relatively low number of cases 
for a meta-regression.  
Anxiety 
The average effect of CS on anxiety (k = 5) was small and non-significant, g = 0.25, 
95% CI [-0.28, 0.77], t = 1.31, p = .259. Evidence favoring an effect of CS on anxiety scores 
was ambiguous, BFH1 = 1.23. Heterogeneity in effect sizes was non-significant, Q(4) = 6.89, p 
= .142, τ2 = 0.07 (SE = 0.12), τ2 BFH1 = 1/1.30, I2 = 43.10, 95% CI [0.00, 94.16]. No 
moderators were tested given the small number of studies available and the non-significant 
heterogeneity in effect sizes.  
Dementia Ratings  
The average effect of CS on dementia ratings (k = 7) was medium-sized and 
significant, g = 0.66, 95% CI [0.02, 1.29], t = 2.54, p = .044. The effect was supported by 
strong evidence, BFH1 = 10.17. The distribution of effect sizes is illustrated in Figure 7. Effect 
size estimates from single studies ranged from g = -0.17 (Coen et al., 2011) to g = 1.75 
(Spector et al., 2001). Three studies reported substantial evidence favoring an effect of CS on 
dementia ratings, and four studies contributed ambiguous evidence. Data were missing from 
one study that did not report group size data (Kolanowski et al., 2016). Heterogeneity in effect 
sizes was significant, Q(6) = 26.13, p < .001, τ2 = 0.34 (SE = 0.25), τ2 BFH1 = 36.81, I2 = 
80.63, 95% CI [50.28, 96.71], but the small number of studies prevented us from testing 
moderator effects.  
Behavior  
The average effect of CS on behavior (k = 11) was small and non-significant, g = 0.28, 
95% CI [-0.60, 1.17], t = 0.71, p = .492. Evidence favoring the absence of an effect of CS on 
behavior measures was ambiguous, BFH1 = 1/1.19. Heterogeneity in effect sizes was 
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significant, Q(10) = 95.09, p < .001, τ2 = 1.53 (SE = 0.75), τ2 BFH1 = 54,654,671,997.77, I2 = 
95.10, 95% CI [89.54, 98.55], but, again, the small number of studies prevented us from 
testing moderator effects.  
Assessment of Bias 
Risk of Bias  
Figure 8 displays the results of the risk of bias assessment using the Cochrane Risk of 
Bias Tool (Higgins et al., 2011).  
Selection Bias. Participants were allocated to conditions based on a random, 
concealed allocation method in 20 of the 45 included comparisons (44%). In two studies 
(Camargo, Justus, & Retzlaff, 2015; Requena et al., 2006), participants were allocated to 
conditions using the day of arrival, which may result in selection bias if a researcher can 
anticipate when potential participants will be assigned (Higgins et al., 2011).   
Performance Bias. In 37 studies (82%), the effectiveness of CS was compared to 
some form of passive control group. In addition to not controlling for non-specific 
intervention and expectancy effects, participants in a passive control group can 
unambiguously determine that they are not receiving treatment. Thus, the use of a passive 
control also prevents true participant blinding. While Baldelli et al. (2002) did include a 
control activity, we deemed it as not comparable enough to effectively blind participants. 
Baldelli et al.’s (2002) control group engaged only in physical therapy, while the active group 
engaged in physical therapy as well as reality orientation sessions4. On a positive note, most 
studies ensured and reported to have blinded assessors to conditions. 
Attrition and Reporting Bias. We identified overall little bias from attrition and 
reporting, with a low risk of bias in 40 comparisons (89%). The highest attrition rate during 
treatment was 39% observed in Wallis et al. (1983), where participants were excluded if 
 
4 Reclassifying Baldelli et al. (2002) as “unclear risk of bias” for participant blinding did not affect the 
conclusions. 
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completing less than 20% of the study. Importantly though, attrition rates were similar across 
groups. Most studies (82%) reported data on all outcomes mentioned in the respective method 
sections.  
Impact of Risk of Bias 
For each outcome with at least 10 cases, we assessed the impact of the risk of bias on 
the average effect sizes using meta-regression (not preregistered). As for the above analyses, 
we computed BFs to gauge the strength of evidence for each analysis. The sum score of the 
risk of bias ratings was not significantly associated with the average effect size estimates for 
any of those outcomes (global cognition: F(1, 40) = 0.76, p = .388; memory: F(1, 13) = 0.52, 
p = .483; language: F(1, 12) = 0.05, p = .832; quality of life: F(1, 9) = 0.22, p = .649; 
activities of daily living: F(1, 12) = 0.59, p = .457; depression: F(1, 17) = 0.32, p = .578, 
behavior, F(1, 9) = 2.48, p = .150. The evidence substantially supported the absence of an 
association with risk of bias ratings for global cognition (BFH1 = 1/3.96) and activities of daily 
living (BFH1 = 1/3.18), but it was less clear cut for memory (BFH1 = 1/2.84), language (BFH1 = 
1/2.07), quality of life (BFH1 = 1/2.88), and depression symptoms (BFH1 = 1/2.66). The 
evidence was particularly ambiguous for behavior, BFH1 = 1.20. Evidence was likely 
ambiguous for the effects of bias on the average effect size estimates for these outcomes 
because of the relatively low number of cases for meta-regression analyses.  
Publication Bias 
To assess small-study bias, we first visually inspected contour-enhanced funnel plots 
for outcomes with at least 10 cases (see Figure 9). For global cognition, few effect sizes fell 
into the areas of negative effect sizes; however, because many effect sizes also fell into the 
area of non-significance for positive effect sizes, publication bias seems an unlikely cause for 
the pattern. Overall, the funnel plots did not suggest censoring of non-significant effect sizes. 
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Both Egger’s and Begg’s and Mazumdar’s regression were non-significant for these outcomes 
(ps ≥ .116 and ps ≥ .108, respectively).  
Discussion 
This pre-registered systematic review and meta-analysis examined the effectiveness of 
CS for people with dementia on cognitive outcomes, quality of life, activities of daily living, 
mood, and behavior and psychological symptoms. Pooling data from 44 published RCTs and 
considering the Bayesian strength of evidence supporting the presence or absence of average 
effects, the present meta-analysis is the most comprehensive to date.  
CS Improves Performance on Indicators of Global Cognition 
We found a medium effect of CS on global cognition (g = 0.49, 95% CI [0.35, 0.63]) 
that was slightly larger than that reported in previous meta-analyses (e.g., SMD = 0.41 in 
Aguirre et al., 2013) and was supported by decisive evidence (BF > 3,000,000). The effect 
was no longer significant at follow-up assessments 1 to 10 months after the intervention; 
however, estimates at follow-up were based on only nine studies, and the evidence was 
ambiguous. Thus, additional data are needed to gauge long-term benefits of CS on global 
cognition. Whereas we also found substantial evidence for CS benefits on memory, the effect 
on language measures was small, non-significant, and based on ambiguous evidence.  
None of the moderators reached statistical significance; however, we found a 
numerically larger pooled effect size for interventions involving reality orientation than for 
CST. Moreover, evidence decisively supported the benefits of reality orientation, and only 
strongly the effectiveness of CST. We also observed an, albeit non-significant, tendency that 
interventions with multiple components (e.g., additional physical exercise) were more 
effective than those with single components. Only one CST intervention (Buschert et al., 
2011), but four reality orientation interventions (Baglio et al., 2015; Baines et al., 1987; 
Baldelli et al., 2002; Bottino et al., 2005), incorporated additional components, which to some 
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degree confounds effects of multiple components and the difference between CST and reality 
orientation. There was also no significant effect of whether interventions were conducted in 
care or in another context, although effects were numerically larger for the latter. Age, gender, 
and baseline cognitive status did not moderate the effect. However, although the absence of 
moderator effects was supported by largely substantial evidence, we cannot rule out the 
possibility of false-negative findings where the evidence was more ambiguous, especially 
given the overall still relatively low number of studies.  
Evidence for Benefits of CS on Some Secondary Outcomes 
Previous meta-analyses reported positive effects of CS on quality of life (Aguirre et 
al., 2013; Kim et al., 2017) but not for activities of daily living (Aguirre et al., 2013; Kim et 
al., 2017; Kurz et al., 2011). We observed the opposite pattern: there were no CS benefits on 
quality of life but a small yet significant effect on activities of daily living. However, the 
evidence was ambiguous for both outcomes, which may explain the discrepancy. Multiple 
factors can contribute to evidence being ambiguous, for example low statistical power or low 
reliability of the outcome measures. In this case, we could only speculate why the evidence is 
ambiguous. Moreover, we found a positive effect of CS on depressive symptoms and on 
dementia ratings. The evidence was strong in both cases, and relatively consistently positive 
effects were observed in those single studies that contributed at least substantial evidence. 
There was also some tentative evidence that interventions with a longer duration (i.e., higher 
number of weeks) attenuated depressive symptoms more than shorter interventions. 
Therefore, intervention dosage may be an important design factor to consider when targeting 
depression-related outcomes in this population. No significant benefits were found for anxiety 
and behavior symptoms, but the evidence was ambiguous for these outcomes. Hence, a larger 
and stronger evidence base is needed to allow for drawing firm conclusions on the benefits of 
CS on most secondary outcomes and their potential moderators.   
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Lack of Double-Blinded, Actively Controlled Studies 
We detected no publication bias and, overall, risk of biases in the included studies was 
relatively moderate and not systematically associated with study outcomes. However, in most 
studies, participant blinding was inadequate. Of the 44 published RCTs, only 8 compared 
effects of CS to active control groups. As participants in a passive control group can never be 
truly blinded, effects observed could be confounded with effects of participant- or 
experimenter-driven expectancy. Moreover, of those, only five studies designed alternative 
interventions that allowed for distinguishing between CS-specific and generic intervention 
effects such as from engaging in social activities. We identified two double-blinded (but 
strongly underpowered: n = 9 and n = 38) studies where both participants and assessors were 
blind to group allocation (Wallis et al., 1983; Woods, 1979). This is highly problematic as it 
implies that the sizable effect of CS benefits on global cognition could be mainly driven by 
expectancy and non-generic intervention effects. Notably, our additional analyses did not 
suggest a difference in average effect sizes between actively and passively controlled studies; 
however, the absence of a difference on the meta-analytic level cannot rule out such 
undesirable effects in any single study. For example, awareness of being or not being selected 
for a new treatment that includes regular, social activities could affect motivation and mood 
when completing the outcome measures. We do not suggest disregarding the overall positive 
effects of CS, but it warrants caution as to what the mechanisms of these benefits are. For 
example, if regular group activities regardless of the specific contents were sufficient to 
improve cognition and mental health in people with dementia, then there would be no need to 
run full-blown CS programs. Therefore, it is important to evaluate the effectiveness of CS 
over and above generic group activities.  
To address this, future RCTs should include an active control group that completes 
activities comparable to those in the CS group but are assumed not to yield the cognitive 
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benefits of CS. Specifically, (1) the active control group should complete activities with the 
same frequency and duration as the treatment group; (2) the activities should be distinct from 
those included in CS but plausible enough to control for expectancy effects; and (3), as social 
interactions and networks have been found to protect against dementia (Fratiglioni et al., 
2000), the treatment and the control group should have similar levels of staff and peer 
interaction, though the form of staff interaction may differ. For example, in Wallis et al.’s 
(1983) study, the control group was offered activities each day and general conversation was 
encouraged, while orientation topics were only mentioned if it occurred in ordinary 
conversation.  
Arguably, randomly allocating participants to complete activities believed to be 
ineffective is ethically questionable. To avoid this problem, benefits of CS should, ideally, be 
compared to an alternative intervention that is assumed to be potentially effective through 
other mechanisms than CS (see also Bahar-Fuchs et al., 2020). However, there is currently no 
consensus of what aspects of CS are likely to benefit people with dementia. For example, the 
benefits of reality orientation may come from its structured implementation (Bowlby, 1991; 
Voelkel, 1978), but other forms of CS focus on reminiscence or social interaction in a 
specified way. Critically, our moderator analysis did not unambiguously show that either 
approach is superior to the other. 
Are the Benefits Clinically Relevant and Generalizable?  
Cost-effectiveness analysis for CST found that, in the best-case scenario, it is a cost-
effective therapy (Knapp et al., 2006). However, as any intervention, CS inevitably generates 
not only financial but also opportunity costs. Thus, it is important to consider whether any 
effects observed are clinically relevant and generalizable to contexts other than the diagnostic 
settings. The U.S. Food and Drug Administration (FDA, 1989, as cited in Hansen et al., 2012; 
see also Qaseem et al., 2008) define a reduction of ≥ 4 points on the ADAS-Cog as clinically 
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relevant, with distribution-based analyses suggesting  ≥ 3 points (Schrag, Schott, & 
Alzheimer’s Disease Neuroimaging Initiative, 2012). Of the 17 studies that used the ADAS-
Cog, scores on average decreased by 3.50 points more than in the control group after the 
intervention. However, this decrease was primarily due to one outlier (Requena et al., 2006): 
after removing this study, the average difference in the decrease in ADAS-Cog scores was 
2.41. Thus, despite the overall medium effect size, the cognitive changes after CS are 
borderline clinically relevant. Nonetheless, the positive effects of CS on activities of daily 
living, depressive symptoms, and dementia ratings are promising. Except for the effect on 
activities of daily living, these benefits of CS were supported by substantial and strong 
evidence. However, none of the studies assessed whether the cognitive benefits of CS were in 
any way linked to reduced dementia progression, which would be a critical indicator of its 
effectiveness (Ito et al., 2011). Finally, due to the variation in CS interventions, it can be 
difficult to compare interventions even of the same type. Whereas CST is manualized 
(Spector et al., 2006) and has been adapted to multiple cultures (Capotosto et al., 2017; 
Yamanaka et al., 2013), other CS interventions such as reality orientation lack operational 
guides (Bowlby, 1991). To enable the identification of the most effective components of 
successful CS interventions, it is critical for future research to describe the interventions 
administered in greater detail.  
Limitations 
The findings of this systematic review and meta-analysis should be interpreted in the 
context of its limitations. First, our approach of selecting one effect size where multiple 
measures for the same type of outcome were reported (e.g., selecting the ADAS-Cog over the 
MMSE) arguably yielded some loss of information. We made the decision to select one of the 
measures and discarded the other measure(s) reported based on theoretical or empirical 
considerations (e.g., evidence that the ADAS-Cog is a more precise measure of cognition in 
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dementia; Balsis et al., 2015). Alternative approaches would have been to create composite 
scores or to use a multi-level modeling approach that accounts for dependencies in effect 
sizes. However, we opted for our approach as we believe that the benefits of greater construct 
validity outweigh the loss of information from discarding the (overall relatively few) less 
adequate measures.  
Second, although the present study included a considerably larger number of studies 
than previous meta-analyses examining the effectiveness of CS, the overall sample size was 
still relatively small, especially for the analysis of secondary outcomes and moderator 
variables. Thus, statistical power was potentially low for some analyses. Moreover, the 
outcome measures administered in the included studies may vary in their reliability and, thus, 
measurement error may have attenuated the effect sizes. Only few studies reported reliabilities 
of the measures used and, therefore, we were unable to correct for measurement error. To 
address potentially low statistical power and varying reliabilities of outcome measures, we 
reported BFs for all analyses. BFs cannot correct for small sample sizes or measurement error, 
but they provide an estimate of the sensitivity of the given data distinguished between the 
presence or absence of effects by quantifying the evidence available. BFs indicated that the 
evidence was sufficiently strong to support either the presence of average effects (global 
cognition, memory, depression, and dementia ratings; see Table 3) or the absence of effects of 
most potential moderators on global cognition and quality of life (see Table 4). However, 
where the evidence was ambiguous only (i.e., close to 1), the available data were not 
sufficiently sensitive to draw firm conclusions, possibly due to noise from the relatively small 
number of studies, measurement error, or a combination of both. Therefore, findings with low 
BFs should be interpreted cautiously until more data are available.  
Third, studies varied widely in the instruments administered to assess the primary and 
secondary outcomes of interest for the present meta-analysis. For example, to assess activities 
COGNITIVE STIMULATION REVIEW 33 
of daily living, five studies administered the Instrumental Activities of Daily Living scale 
(Lawton & Brody, 1969), three studies used the Barthel Index (Mahoney & Barthel, 1965), 
and the remaining studies used either the MOSES self-care scale (Helmes et al., 1987; two 
studies), the Disability Assessment for Dementia (Gélinas et al., 1999; De Vreese et al., 2008; 
two studies), Stewart's Activities of Daily Living (Stewart, 1980; one study), or a 
performance-based test (Graessel et al., 2009; one study). Although these instruments all have 
been designed to assess broadly the same construct – activities of daily living – they may 
differ in what specific activities they place emphasis on. Thus, between-study heterogeneity 
may partly be driven by the variability in outcome measures. Different instruments may also 
vary in terms of internal and test-retest reliability, adding further noise to the meta-analytic 
estimates. Therefore, it is possible that the heterogeneity in outcome measures contributed to 
the ambiguity in evidence we observed for some of the meta-analytic average effects.  
Finally, the reporting in the original studies was often insufficient to extract the 
relevant data. For example, incomplete statistical reporting prevented us from conducting a p-
curve analysis we pre-registered. Moreover, because of the lack of detail in descriptions of 
samples and interventions, data were missing for several potentially critical moderators. For 
example, descriptive data on ethnicity was missing in 31 of 44 studies; thus, it is impossible to 
gauge whether the data are representative for the population of people with dementia. 
Moreover, 16 of the included studies did not report clinical severity of their sample (i.e., 
baseline MMSE scores). The lack of data limits the representativeness of the absence of a 
moderating effect of clinical severity on global cognition and depression, and it prevented us 
from examining effect of this moderator on memory, language, and quality of life. 
Furthermore, the MMSE provides only information of clinical severity of cognitive 
impairments; ideally, and especially given that the present meta-analysis found evidence for 
CS benefits on non-cognitive outcomes, clinical severity should be assessed more holistically 
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through clinical dementia ratings. However, only seven of the included studies provided such 
data. Knowing who benefits most from CS interventions is critical both for practitioners 
treating people with dementia as well as for further developing maximally effective 
interventions.  
Conclusions 
In this systematic review and meta-analysis, we examined the evidence for the 
effectiveness of CS, a group of interventions recommended by NICE (2018) for treating 
dementia. We found a medium average effect of CS on indicators of global cognition (e.g., 
ADAS-Cog, MMSE) supported by decisive Bayesian evidence. Additional positive effects on 
memory and secondary outcomes – activities of daily living, depression, and dementia rating 
– were mostly supported by substantial, and sometimes strong, evidence. However, only few 
studies tested the longer-term benefits of CS, yielding inconclusive evidence at this point. 
Furthermore, the review highlighted a lack of double-blinded, actively controlled studies, and 
relatively low clinical relevance of the effects. To optimize treatment of dementia, future 
RCTs should evaluate longer-term benefits of CS, will need better controls for non-specific 
intervention effects, and more directly test generalization of effects beyond diagnostic 
measures of global cognition. This study concludes that the benefits of CS for people with 
dementia are promising. Practitioners may find that the medium average effect size, relatively 
low cost and absence of negative side-effects of CS outweigh that the effects are borderline 
clinically relevant. Importantly, however, a stronger evidence basis for the long-term 
effectiveness of CS beyond generic group activities is urgently needed before definitive 
practice recommendations can be made.  
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Table 1 
Verbal Labels for Interpreting Bayes Factors 
Bayes factor  
H1 H0 Interpretation of evidence 
> 100 < 1/100 Decisive 
30 to 100 1/100 to 1/30 Very strong 
10 to 30 1/30 to 1/10 Strong 
3 to 10 1/10 to 1/3 Substantial 
1 to 3 1/3 to 1 Ambiguous 
1 1 No evidence 
Note. Adapted from Wetzels and Wagenmakers (2012). 
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Table 2 
Sample and Intervention Characteristics, and Effect Sizes and Strength of Evidence of Cognitive Change for Studies Included in the Review 
Study N Age Gender MMSE Type Components Duration Frequency Context g [95% CI] BF [sensitivity] 
Alves et al. (2014) 17 79.60 70.00 - other multiple 6 3 in care 0.20 [-0.72, 1.12] 1/1.38 [1/1.14, 1/1.92] 
Baglio et al. (2015) 50 75.61 53.57 19.50 RO+ multiple 10 3 other 1.71 [1.07, 2.36] >100 [>100, >100] 
Baines et al. (1987) 10 81.40 - - RO+ multiple 4 5 in care -0.02 [-1.14, 1.10] 1/1.59 [1/1.28, 1/2.23] 
Baldelli et al. (1993) 23 - 100 18.50 RO+ single 12 3 in care 1.46 [0.56, 2.36] 24.07 [14.44, 33.21] 
Baldelli et al. (2002) 87 79.60 70.42 - RO+ multiple 4 5 in care 0.83 [0.28, 1.38] 19.52 [13.69, 21.10] 
Bottino et al. (2005) 13 74.67 83.30 - RO+ multiple 20 1 other 0.38 [-0.64, 1.41] 1/1.11 [1.02, 1/1.42] 
Breuil et al. (1994) 56 76.10 68.75 19.50 other single 5 2 other 0.71 [0.18, 1.25] 9.37 [7.28, 9.21] 
Buschert et al. (2011) 15 77.30 50.00 24.00 CST+ multiple 20 1 other 0.13 [-0.83, 1.09] 1/1.49 [1/1.20, 1/2.08] 
Camargo et al. (2015) 14 80.86 42.86 20.50 RO+ single 26 1 other 0.82 [-0.20, 1.85] 1.71 [1.60, 1.60] 
Capotosto et al. (2017) 39 88.25 75.00 22.00 CST+ single 7 2 in care 0.29 [-0.33, 0.90] 1/1.14 [1.06, 1/1.62] 
Chapman et al. (2004)a 54 - - 21 other single 8 1 other 0.12 [-0.48, 0.72] 1/1.72 [1/1.28, 1/2.65] 
Coen et al. (2011) 25 78.40 35.71 16.50 CST+ single 7 2 in care -0.19 [-0.95, 0.57] 1/2.47 [1/1.72, 1/3.99] 
Cove et al. (2014) 59 76.15 42.21 24.00 CST+ single 14 1 other 0.15 [-0.37, 0.68] 1/1.63 [1/1.21, 1/2.54] 
D'Onofrio et al. (2015) 90 76.67 51.10 20.00 RO+ single 16 1 other 0.24 [-0.17, 0.66] 1/1.05 [1.22, 1/1.60] 
Ferrario et al. (1991) 19 82.5 42.00 - RO+ single 21 5 in care 0.34 [-0.59, 1.27] 1/1.15 [1.00, 1/1.51] 
Gibbor et al. (in press) 29 86.24 42.90 20.94 CST+ single 7 2 in care 0.40 [-0.32, 1.12] 1.09 [1.22, 1/1.20] 
Haight et al. (2006) 30 - - 16.93 other single 6 1 in care 1.25 [0.49, 2.02] 28.48 [17.45, 37.37] 
Ishizaki et al. (2002) 25 75.9 64.29 26.4 RO+ multiple 24 1 other 0.80 [0.01, 1.60] 2.86 [2.47, 2.76] 
Kim et al. (2016) 53 78.44 75.00 - other single 24 5 other 0.42 [-0.13, 0.97] 1.58 [1.70, 1.20] 
Kolanowski et al. (2016)b 283 85.28 62.40 - other single 4 5 other -0.03 [-0.26, 0.20] 1/5.48 [1/3.04, 1/10.25] 
Lopez et al. (2020) 20 83.3 80.00 18.1 other multiple 24 3 other  0.06 [-0.78, 0.90] 1/1.70 [1/1.31, 1/2.50] 
Luttenberger et al. (2012) 61 84.10 90.00 12.00 other multiple 52 6 in care 0.40 [-0.10, 0.90] 1.62 [1.77, 1.21] 
Maci et al. (2012) 14 75.00 57.14 20.00 other multiple 12 5 other 0.33 [-0.65, 1.32] 1/1.17 [1/1.02, 1/1.52] 
Menna et al. (2016) 30 74.95 70.00 - RO+ single 24 1 other 1.36 [0.54, 2.17] 32.17 [19.24, 43.76] 
Niu et al. (2010) 32 80.56 12.50 16.94 CST+ single 10 2 in care 0.31 [-0.37, 0.99] 1/1.10 [1.07, 1/1.53] 
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Onder et al. (2005) 137 75.70 73.00 20.50 RO+ single 25 3 other 0.21 [-0.13, 0.55] 1/1.09 [1.23, 1/1.74] 
Onor et al. (2007) 16 68 37.50 23.12 RO+ multiple 24 3 other 0.00 [-0.93, 0.93] 1/1.73 [1/1.34, 1/2.54] 
Orrell et al. (2017) 273 - 46.00 20.00 CST+ single 25 3 other -0.06 [-0.30, 0.18] 1/6.39 [1/3.49, 1/12.01] 
Paddick et al. (2017) 34 - 87.50 - CST+ single 7 2 other 0.95 [0.26, 1.65] 9.44 [6.76, 10.49] 
Piras et al. (2017) 35 83.81 71.43 22.00 CST+ single 7 2 other 0.35 [-0.32, 1.01] 1.00 [1.16, 1/1.36] 
Quayhagen et al. (1995) 53 - - - other single 12 6 other 0.41 [-0.13, 0.94] 1.53 [1.66, 1.15] 
Quintana-Hernandez et al. 
(2016) 62 - 
- 
24.00 other single 96 3 other 0.74 [0.23, 1.25] 15.40 [11.39, 15.66] 
Requena et al. (2006) 36 77.00 72.22 - CST+ single 104 5 other 1.43 [0.71, 2.15] >100 [>100, >100] 
Schecker et al. (2013) 27 76.50 75.00 18.50 other single 24 0 other 0.51 [-0.24, 1.26] 1.38 [1.44, 1.12] 
Spector et al. (2001) 27 - - - CST+ single 7 2 other 0.40 [-0.37, 1.16] 1.04 [1.17, 1/1.26] 
Spector et al. (2003) 201 85.70 83.48 17.00 CST+ single 7 2 in care 0.29 [0.01, 0.57] 2.90 [3.38, 1.94] 
Tadaka et al. (2007), 
comp. 1 
21 82.5 66.67 14.6 other single 8 1 other 0.02 [-0.80, 0.84] 1/1.80 [1/1.37, 1/2.70] 
Tadaka et al. (2007), 
comp. 2 
36 85.3 72.22 19.8 other single 8 1 other 0.68 [0.02, 1.33] 3.11 [2.76, 2.84] 
Tarraga et al. (2015) 28 77.4 87.50 22.5 other multiple 24 5 other 0.13 [-0.59, 0.86] 1/1.60 [1/1.24, 1/2.37] 
Tsantali et al. (2017)a 38 73.3 - - other single 16 3 other -0.43 [-1.06, 0.21] 1/4.05 [1/2.49, 1/7.13] 
Wallis et al. (1983) 38 71.80 27.78 - RO+ single 13 5 in care 0.12 [-0.50, 0.74] 1/1.71 [1/1.28, 1/2.62] 
Wang et al. (2007) 102 79.76 52.90 14.33 other single 8 1 in care 0.46 [0.07, 0.85] 5.38 [5.07, 4.31] 
Woods et al. (1979) 9 - - - RO+ single 20 5 in care 1.12 [-0.15, 2.40] 1.83 [1.62, 1.85] 
Yamagami et al. (2012) 53 85.50 96.40 - RO+ multiple 12 2 in care -0.02 [-0.55, 0.51] 1/2.53 [1/1.70, 1/4.21] 
Young et al. (2019) 101 80.53 40.60 19 other multiple 7 2 other 1.22 [0.80, 1.64] >100 [>100, >100] 
Note. Age (years), gender (percentage of females) and Mini-Mental State Examination score are given in means at baseline. Duration is given in 
weeks; frequency is given in sessions per week. Bayes factors unambiguously supporting the presence of a cognitive stimulation effect (i.e., 
Bayes factors greater than 3) or unambiguously supporting the absence of a cognitive stimulation effect (i.e., Bayes factors smaller than 1/3) are 
printed in bold. Bayes factors from sensitivity analyses for small-effect priors (d = 0.2) and large-effect priors (d = 0.8) are provided in angular 
brackets. MMSE = Mini-Mental State Examination; CST+ = cognitive stimulation therapy with or without additional cognitive stimulation 
components (e.g., physical exercise); RO+ = reality orientation with or without additional cognitive stimulation components (e.g., physical 
exercise); BF = Bayes factor.  
a Effect size from follow-up. b Effect size from memory measure.  
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Table 3 
Cognitive Stimulation Effects on Primary and Secondary Outcomes 
Outcome k g SE CI BF [sensitivity] I2 [95% CI] τ2 BF τ2  
Primary Outcomes    
Global cognition         
Posttest 42 0.49 0.07 [0.35, 0.63] >100 [>100, >100] 54.68 [28.52, 72.56] 0.1 (0.05) < 100 
Follow-up 9 0.22 0.14 [-0.09, 0.54] 1.67 [2.19, 1.05] 19.10 [0.00, 84.37] 0.03 (0.07) 1/1.17 
Memory 15 0.34 0.13 [0.06, 0.62] 9.74 [10.44, 6.83] 53.59 [9.27, 83.28] 0.12 (0.09) 9.09 
Language 14 0.10 0.27 [-0.47, 0.67] 1/1.89 [1/1.35, 1/3.03] 88.87 [77.94, 95.94] 0.83 (0.38) < 100 
Secondary Outcomes    
Quality of life 11 0.16 0.15 [-0.16, 0.48] 1.07 [1.54, 1/1.59] 25.64 [0.00, 92.42] 0.04 (0.06) 1.31 
Activities of daily living 14 0.17 0.07 [0.02, 0.32] 2.04 [2.99, 1.19] 20.38 [0.00, 55.29] 0.02 (0.03) 1/1.04 
Depression 19 0.46 0.15 [0.15, 0.78] 27.26 [23.57, 22.38] 74.73 [53.71, 89.65] 0.28 (0.14) < 100 
Anxiety 5 0.25 0.19 [-0.28, 0.77] 1/1.23 [1.11, 1/2.00] 43.10 [0.00, 94.16] 0.07 (0.12) 1/1.30 
Dementia 7 0.66 0.26 [0.02, 1.29] 10.17 [7.69, 9.53] 80.63 [50.28, 96.71] 0.34 (0.25) 36.81 
Behavior 11 0.28 0.40 [-0.60, 1.17] 1/1.19 [1.01, 1/1.67] 95.10 [89.54, 98.55] 1.53 (0.75) < 100 
Note. Bayes factors unambiguously supporting the presence of a cognitive stimulation effect (i.e., Bayes factors greater than 3) or unambiguously 
supporting the absence of a cognitive stimulation effect (i.e., Bayes factors smaller than 1/3) are printed in bold. Bayes factors from sensitivity 
analyses for small-effect priors (d = 0.2) and large-effect priors (d = 0.8) are provided in angular brackets. CI = confidence interval; BF = Bayes 
factor.  
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Table 4 
Effects of Moderators on the Benefits of Cognitive Stimulation 
Moderator k F dfs p BF [sensitivity] 
Cognition 
Type of intervention 27 1.51 1, 25 .230 1/2.33 [1/1.35, 1/3.45] 
Number of CS components 42 0.09 1, 40 .766 1/5.56 [1/2.56, 1/8.33] 
Intervention context 34 0.64 1, 32 .429 1/4.00 [1/2.08, 1/6.25] 
Intervention duration 42 1.32 1, 40 .258 1/3.23 [1/1.59, 1/5.00] 
Intervention frequency 42 0.02 1, 40 .889 1/5.56 [1/2.33, 1/9.09] 
Intervention sessions 42 1.41 1, 40 .243 1/3.03 [1/1.49, 1/4.76] 
Age 34 0.61 1, 32 .439 1/4.00 [1/1.85, 1/6.25] 
Gender distribution 36 0.57 1, 34 .454 1/4.00 [1/1.89, 1/6.25] 
Clinical severity (baeline 
MMSE) 
28 < 0.01 1, 26 .971 1/4.76 [1/2.08, 1/7.69] 
Memory 
Intervention duration 15 0.44 1, 13 .520 1/3.03 [1/1. 61, 1/4.55] 
Intervention frequency 15 0.69 1, 13 .422 1/2.00 [1/1.20, ½.94] 
Intervention sessions 15 0.16 1, 13 .692 1/3.23 [1/1.75, 1/5.26] 
Age 12 1.69 1, 10 .223 1/1.69 [1/1.25, 1/2.38] 
Gender distribution 12 0.19 1, 10 .676 1/2.37 [1/1.42, 1/3.35] 
Language 
Intervention duration 14 0.06 1, 12 .813 1/1.96 [1/1.30, 1/2.63] 
Intervention frequency 14 0.49 1, 12 .497 1/1.75 [1/1.16, 1/2.38] 
Intervention sessions 14 0.08 1, 12 .788 1/1.96 [1/1.30, 1/2.78] 
Age 11 3.75 1, 9 .085 1.99 [1.59, 1.84] 
Gender distribution 10 2.25 1, 8 .172 1.28 [1.27, 1.14] 
Quality of Life 
Intervention duration 11 0.09 1, 9 .774 1/3.18 [1/1.59, 1/5.00] 
Intervention frequency 11 0.07 1, 9 .804 1/3.18 [1/1.60, 1/4.93] 
Intervention sessions 11 0.02 1, 9 .904 1/3.77 [1/1.83, 1/5.74] 
Age 11 0.05 1, 9 .822 1/2.80 [1/1.51, 1/4.19] 
Gender distribution 10 > 0.01 1, 8 .958 1/3.27 [1/1.71, 1/4.81] 
Depression 
Intervention duration 19 2.29 1, 17 .149 1/1.14 [1.13, 1/1. 54] 
Intervention frequency 19 1.89 1, 17 .187 1/1.22 [1.09, 1/1.64] 
Intervention sessions 19 4.90 1, 17 .041a 2.53 [2.35, 2.11] 
Age 16 2.80 1, 14 .116 1.05 [1.23, 1/1.15] 
Gender distribution 17 0.27 1, 15 .614 1/2.44 [1/1.39, 1/3.57] 
Clinical severity (baeline 
MMSE) 
13 2.06 1, 11 .179 1/1.30 [1.03, 1/1.75] 
Note. Bayes factors unambiguously supporting the presence of a cognitive stimulation effect 
(i.e., Bayes factors greater than 3) or unambiguously supporting the absence of a cognitive 
stimulation effect (i.e., Bayes factors smaller than 1/3) are printed in bold. Bayes factors from 
sensitivity analyses for small-effect priors (d = 0.2) and large-effect priors (d = 0.8) are 
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provided in angular brackets. MMSE = Mini-Mental State Examination (Folstein et al., 1975) 
BF = Bayes factor. 
a After removal of one outlier study (Requena et al., 2006; see text for details), this 
association reversed from being significantly negative to being significantly positive (p = 
.027).  
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Figure 1 
Flowchart of Systematic Search and Study Selection 
 
Note. CS = cognitive stimulation; RCT = randomized-controlled trial.  
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Figure 2 
Average Effects of Cognitive Stimulation on Global Cognition 
 
Note. Effect sizes are weighted averages; error bars represent 95% confidence intervals. The 
filling of the circles reflects the direction of evidence (black: alternative hypothesis; white: 
null hypothesis) and their size the strength of evidence in terms of Bayes factors (BFs; small: 
ambiguous evidence with BFs between 1/3 and 3; large: at least substantial evidence with BFs 
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≥ 3 or ≤ 1/3). The solid vertical line represents the weighted average effect size (g = 0.49), the 
dotted line represents the reference line at zero.  
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Figure 3 
Moderator Effects on the Benefits of Cognitive Stimulation for Global Cognition 
 
Note. Effect size estimates are weighted averages for the subgroups of each level of tested 
categorical moderator. Error bars represent 95% confidence intervals. Bayes factors were ≥ 3 
for all subgroup effects. The solid vertical line represents the weighted average effect size (g 
= 0.49) across all comparisons, the dotted line represents the reference line at zero. CST+ = 
cognitive stimulation therapy with or without additional cognitive stimulation components 
(e.g., physical exercise); RO+ = reality orientation with or without additional cognitive 
stimulation components (e.g., physical exercise); CS = cognitive stimulation.  
COGNITIVE STIMULATION REVIEW 65 
Figure 4 
Average Effects of Cognitive Stimulation on Activities of Daily Living 
 
Note. Effect sizes are weighted averages; error bars represent 95% confidence intervals. The 
filling of the circles reflects the direction of evidence (black: alternative hypothesis; white: 
null hypothesis) and their size the strength of evidence in terms of Bayes factors (BFs; small: 
ambiguous evidence with BFs between 1/3 and 3; large: at least substantial evidence with BFs 
≥ 3 or ≤ 1/3). The solid vertical line represents the weighted average effect size (g = 0.17), the 
dotted line represents the reference line at zero. 
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Figure 5 
Average Effects of Cognitive Stimulation on Symptoms of Depression 
 
Note. Effect sizes are weighted averages; error bars represent 95% confidence intervals. The 
filling of the circles reflects the direction of evidence (black: alternative hypothesis; white: 
null hypothesis) and their size the strength of evidence in terms of Bayes factors (BFs; small: 
ambiguous evidence with BFs between 1/3 and 3; large: at least substantial evidence with BFs 
≥ 3 or ≤ 1/3). The solid vertical line represents the weighted average effect size (g = 0.46), the 
dotted line represents the reference line at zero.  
 
  
COGNITIVE STIMULATION REVIEW 67 
Figure 6 
Relationship Between Intervention Duration, Intensity, and Dosage and Cognitive Stimulation 
Effect Size on Depression 
 
Note. Scatterplots relating weighted average effect sizes of cognitive stimulation on 
depression to intervention duration (left), intensity (center), and their interaction (i.e., total 
number of sessions, right). The red dot represents the study by Requena et al. (2006), with the 
red regression line representing the trend when including this study, and the blue regression 
line representing the trend when excluding this study.  
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Figure 7 
Average Effects of Cognitive Stimulation on Ratings of Dementia Symptoms 
 
Note. Effect sizes are weighted averages; error bars represent 95% confidence intervals. The 
filling of the circles reflects the direction of evidence (black: alternative hypothesis; white: 
null hypothesis) and their size the strength of evidence in terms of Bayes factors (BFs; small: 
ambiguous evidence with BFs between 1/3 and 3; large: at least substantial evidence with BFs 
≥ 3 or ≤ 1/3). The solid vertical line represents the weighted average effect size (g = 0.66), the 
dotted line represents the reference line at zero. 
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Figure 8 
Risk of Bias Ratings 
 
Note. Risk of bias was rated using the Cochrane Risk of Bias Tool (Higgins et al., 2011).  
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Figure 9 
Contour-Enhanced Funnel Plots of Effect Sizes of Cognitive Stimulation on Primary and 
Secondary Outcomes 
 
Note. Primary outcomes are presented in the top row, secondary outcomes in the middle and 
bottom row. The solid vertical line represents the null hypothesis of d = 0. The tilted solid, 
dashed, and dotted lines show levels of significance for the effect sizes at α = .05, α = .01, and 
α = .001, respectively. Thus, the areas between the tilted solid and dashed lines, the dashed 
and dotted lines, and beyond the dotted lines represent p < .05, p < .01, and p < .001, 
respectively. Effect sizes within the inner white area are non-significant.  
 
